////////////Evolink, a Skolkovo resident scientific and production biotechnology company, has been creating and producing innovative drugs for livestock and poultry farming since 2017.
Evolink, a Skolkovo resident scientific and production biotechnology company, has been creating and producing innovative drugs for livestock and poultry farming since 2017.
About us
50+
companies are already cooperating with us
14
Drugs in the portfolio
8
Years in the industry
50+
Highly qualified specialists and scientists in the team
1
Own collection of relevant strains for creating effective vaccines
N.V. Pimenov
"A company with great prospects. The guys from Evolink are moving in the right direction - the problem of avian flu, due to the epizootic situation in the world, requires an immediate solution."
Professor of the Russian Academy of Sciences, Doctor of Biological Sciences
P.E. Shkarlat
"Food security is impossible without effective and advanced domestic solutions. Evolink's products are an example of how Russian science effectively solves the industry's production problems."
Veterinarian, Candidate of Biological Sciences
N.V. Pimenov
"A company with great prospects. The guys from Evolink are moving in the right direction - the problem of avian flu, due to the epizootic situation in the world, requires an immediate solution."
Professor of the Russian Academy of Sciences, Doctor of Biological Sciences
P.E. Shkarlat
"Food security is impossible without effective and advanced domestic solutions. Evolink's products are an example of how Russian science effectively solves the industry's production problems."
Veterinarian, Candidate of Biological Sciences
These are viruses that can selectively find and destroy certain groups of bacteria. At the same time, bacteriophages are able to multiply in these bacteria, thereby increasing their concentration. Unlike antibiotics, bacteriophage-based drugs do not affect the normal microflora of the gastrointestinal tract.
Yes, bacteriophages are completely safe for humans and animals, as they are capable of infecting only prokaryotic cells (bacteria). Bacteriophages are unable to affect eukaryotic cells of humans, animals and plants, which indicates their safety.
At the first stage, clinical and pathological material is selected from the enterprise for diagnostic studies and isolation of pure cultures of pathogenic microorganisms. At the second stage, bacteriophages are selected from the working collection. At the third stage, the formulation of the finished dosage form is carried out, its control and release into circulation. At the fourth stage, together with Evolink specialists, the most optimal scheme for the use of the drug, adapted to a specific enterprise, is being developed.
Initially, we apply high antigen activity and use a world-class adjuvant, which allows us to shorten the lag phase and trigger a more intense and prolonged immune response. In addition, since 2016, we have been continuously replenishing our bank of epizootically significant viruses in order to technologically select them for the development of new and relevant immunobiological drugs.
According to the State Pharmacopoeia of the Russian Federation — OFS "Bacteriophages": the collection of industrial bacterial strains used in the production of bacteriophages must be updated annually with freshly isolated strains from patients by at least one third. In view of this, it is possible to adjust the phage composition of the drug, which in turn minimizes the rate of development of resistance.
Ask us a question
By clicking on the "Submit" button, I agree to the "Privacy Policy"